{{Drugbox
| IUPAC_name = ''N''-[(2''S'')-1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide
| image = AB-FUBINACA.svg

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I<!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_DE = Anlage II
| legal_status = Illegal in China
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1185282-01-2
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 58124325
| smiles = CC(C)[C@H](NC(=O)c1nn(Cc2ccc(F)cc2)c3ccccc13)C(N)=O
| ChemSpiderID = 28537614
| UNII = I7PZF0KTFK
| StdInChI = 1S/C20H21FN4O2/c1-12(2)17(19(22)26)23-20(27)18-15-5-3-4-6-16(15)25(24-18)11-13-7-9-14(21)10-8-13/h3-10,12,17H,11H2,1-2H3,(H2,22,26)(H,23,27)/t17-/m0/s1
| StdInChIKey = AKOOIMKXADOPDA-KRWDZBQOSA-N

<!--Chemical data-->
| C=20 | H=21 | F=1 | N=4 | O=2
| molecular_weight = 368.40 g/mol
}}

'''AB-FUBINACA''' is a drug that acts as a potent [[agonist]] for the [[cannabinoid receptor]]s, with ''K''<sub>i</sub> values of 0.9&nbsp;nM at CB<sub>1</sub> and 23.2&nbsp;nM at CB<sub>2</sub>, and [[EC50|EC<sub>50</sub>]] values of 1.8&nbsp;nM at CB<sub>1</sub> and 3.2&nbsp;nM at CB<sub>2</sub>.<ref>{{cite journal | author1=Samuel D Banister | author10=Michelle Glass | author11=Mark Connor | author12=Iain S McGregor | author13=Michael Kassiou | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA | date=July 2015 | author2=Michael Moir | author3=Jordyn Stuart | author4=Richard C Kevin | author5=Katie E Wood | author6=Mitchell Longworth | author7=Shane M Wilkinson | author8=Corinne Beinat | author9=Alxendra S Buchanan | journal=ACS Chemical Neuroscience | volume=6 | issue=9 | pages=1546–1559 | doi=10.1021/acschemneuro.5b00112 | pmid=26134475}}</ref><ref>{{cite journal | author1=Hsin-Hung Chen | url=http://onlinelibrary.wiley.com/doi/10.1002/jcb.25421/abstract | title=Detection and Characterization of the Effect of AB-FUBINACA and its Metabolites in a Rat Model | date=April 2016 | author2=Aybike Dip | author3=Mostafa Ahmed | author4=Michael L. Tan | author5=Jeffrey P. Walterscheid | author6=Hua Sun | author7=Ba-Bie Teng | author8=Ashraf Mozayani | journal=Journal of Cellular Biochemistry | volume=117 | issue=4 | pages=1033–1043 | doi=10.1002/jcb.25421 | pmid=26517302}}</ref><ref>{{cite journal | author1=Svante Vikingsson | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1896/abstract | title=Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry | author2=Henrik Gréen | author3=Linda Brinkhagen | author4=Shahzabe Mukhtar | author5=Martin Josefsson | journal=Drug Testing and Analysis | volume=8 | issue=9 | pages=950–6 | date=November 2015 | doi=10.1002/dta.1896 | pmid=26560240}}</ref> It was originally developed by [[Pfizer]] in 2009 as an [[analgesic]] medication,<ref>[http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009106982 Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982]</ref> but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in [[synthetic cannabis]] blends in Japan,<ref>{{cite journal | first1=N. | last1=Uchiyama | url=https://link.springer.com/article/10.1007%2Fs11419-012-0171-4 | title=New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products | last2=Matsuda | first2=S. | last3=Wakana | first3=D. | last4=Kikura-Hanajiri | first4=R. | last5=Goda | first5=Y. | journal=Forensic Toxicology | date=January 2013 | volume=31 | issue=1 | pages=93–100 | doi=10.1007/s11419-012-0171-4}}</ref> along with a related compound [[AB-PINACA]] which had not previously been reported.

==Side effects==

AB-FUBINACA has been linked to hospitalizations and deaths due to its use.<ref>{{cite journal | url=http://www.nejm.org/doi/full/10.1056/NEJMp1505328 | title=Synthetic Cannabinoid–Related Illnesses and Deaths |author1=Jordan Trecki |author2=Roy R. Gerona |author3=Michael D. Schwartz | journal=New England Journal of Medicine |date=July 2015  | volume=373 | issue=2 | pages=103–107 | doi=10.1056/NEJMp1505328 | pmid=26154784}}</ref><ref>{{cite journal | author1=Janez Klavž | url=http://www.sciencedirect.com/science/article/pii/S0379073816000372 | title=Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC | date=August 2016 | author2=Maksimiljan Gorenjak | author3=Martin Marinšek | journal=Forensic Science International | volume=265 | pages=121–124 | doi=10.1016/j.forsciint.2016.01.018 | pmid=26890319}}</ref>

==Legality==

In January 2014, AB-FUBINACA was designated as a [[Schedule I controlled substance]] in the United States.<ref>{{cite web | url=http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm | title=Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I | publisher=Drug Enforcement Administration, Department of Justice | date=10 January 2014 | accessdate=21 July 2015}}</ref>

AB-FUBINACA is an [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled substance in Germany as of November 2014.<ref>{{cite web | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html | title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel) | accessdate=22 June 2015 | language=German}}</ref>

As of October 2015 AB-FUBINACA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==See also==
{{Colbegin}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-CHFUPYCA]]
* [[AB-CHMINACA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[Benzydamine]]
* [[MDMB-CHMICA]]
* [[MDMB-FUBINACA]]
* [[NESS-040C5]]
* [[PF-03550096]]
* [[PX-3]]
{{Colend}}

==References==
<references />

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:Indazoles]]
[[Category:Indazolecarboxamides]]


{{cannabinoid-stub}}